<DOC>
	<DOCNO>NCT02530697</DOCNO>
	<brief_summary>Mucocutaneous leishmaniasis endemic central region Brazil country worldwide . The standard treatment meglumine antimoniate high rate important adverse effect . This interventional study consist randomize clinical trial access efficacy safety association miltefosine pentoxifylline compare meglumine antimoniate pentoxifyline .</brief_summary>
	<brief_title>The Association Miltefosine Pentoxifylline Treat Mucosal Leishmaniasis : A Clinical Trial Brazil</brief_title>
	<detailed_description />
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Mucocutaneous</mesh_term>
	<mesh_term>Pentoxifylline</mesh_term>
	<mesh_term>Meglumine antimoniate</mesh_term>
	<mesh_term>Miltefosine</mesh_term>
	<criteria>Mucosal leishmaniasis , treat least 6 month without treatment leishmaniasis ; Ages 18 80 year old ; Fertile female patient use least two contraceptive method ( hormonal barrier ) ; Agree participate study sign inform consent term . Use leishmanicidal drug six month prior ; Clinical laboratorial evidence electrocardiographic disorder ; Renal , hepatic , cardiac disease , uncontrolled diabetes AIDS ; Hypersensitivity meglucamine antimoniate ; Pregnancy lactation ; Fertile female agree use contraceptive method ; Patients agree inform consent term .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Leishmaniasis</keyword>
	<keyword>Mucocutaneous</keyword>
	<keyword>Miltefosine</keyword>
	<keyword>Pentoxifylline</keyword>
</DOC>